Lymphoma Treatment Market Demand and Trends 2034
Global Lymphoma Treatment Market Growth, Size, Trends Analysis - By Type, By Drugs - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: HLCA25318 | Pages: 1 - 273 | Formats*: |
| Category : Healthcare | |||
Global Lymphoma Treatment Market Introduction and Overview
According to SPER Market Research, the Global Lymphoma Treatment Market is estimated to reach USD 16.88 billion by 2034 with a CAGR of 8.58%.
The report includes an in-depth analysis of the Global Lymphoma Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The Global Lymphoma Treatment Market was valued at USD 7.41 billion in 2024, and it is expected to rise at a 8.58% CAGR from 2025 to 2034. The growing use of targeted medicines and immunotherapies has changed lymphoma treatment, providing higher efficacy and fewer adverse effects than traditional chemotherapy. Monoclonal antibodies, CAR-T cell treatments, and immune checkpoint inhibitors have transformed the industry and increased patient survival rates. The FDA's quick clearance of new medicines, combined with ongoing clinical trials, has supported market growth.
By Type Insights
Non-Hodgkin lymphoma dominated the market in 2024. Novel medicines, including targeted drugs, monoclonal antibodies, and CAR-T cell therapies, have improved treatment outcomes and expanded market opportunities. The combination of unmet needs, research, and clinical trials for NHL has led to the rapid approval of innovative medicines in the market. NHL is now the most frequent type of lymphoma, surpassing Hodgkin lymphoma (HL), owing to its rising prevalence, particularly in older people and those with immunosuppressive diseases. NHL treatment is experiencing growth in the lymphoma market due to improved healthcare infrastructure, payment regulations, and increased awareness of early detection.
By Drugs Insights
Rituxan (MabThera) dominated the market and had the highest revenue share in 2024, owing to its proven efficacy and widespread use across a variety of indications, including non-Hodgkin lymphoma (NHL). Its high prescription rates in major markets, including the United States and Europe, demonstrate its usefulness in treatment regimens. Furthermore, ongoing clinical investigations and label expansions are broadening its applications and strengthening its commercial position. The rising prevalence of lymphoma, as well as the desire for effective therapy, all contribute to Rituxan's continued success in this competitive terrain. Keytruda is predicted to expand at the quickest CAGR during the forecast period, owing to its position as a major immunotherapy option, particularly in advanced or refractory cases.
Regional Insights
North America had the biggest market share in 2024. This region's exceptional healthcare infrastructure, high healthcare expenditure, and presence of prominent pharmaceutical companies all contribute to its success. This region is leading the way in the adoption of new therapies, including targeted drugs, immunotherapies, and CAR-T cell treatments, thanks to significant pre-commercial R&D investment and a favorable regulatory environment led by the U.S. and Health Canada. The American Cancer Society reports thousands of new instances of Nodal Lymphoma (NHL) in the United States each year, driving market growth. Strong reimbursement policies and government measures to improve access to cancer therapies would strengthen the North American market. The region's strong research institutes and clinical trials drive innovation and make it a leading force in lymphoma therapy globally.
Market Competitive Landscape
Gilead's Kite Pharma and Novartis top the CAR-T category, with extensive production footprints and global logistics. Pfizer and Regeneron are at the forefront of the antibody market, pushing forward with next-generation bispecifics and subcutaneous forms. Mid-cap biotechs drive innovation, as seen by Lyell Immunopharma's acquisition of ImmPACT Bio, which has dual-antigen CAR-T capacity. Lyell Immunopharma. "Lyell Immunopharma to Acquire ImmPACT Bio," ir.lyell.com. Capacity growth remains a strategic imperative: Legend Biotech's expansion of Carvykti production shows the race for supply and profit advantages. Another competitive axis is subcutaneous formulation expertise, with device collaborations resulting in unique injectable systems.
Recent Developments:
In May 2024, Bristol Myers Squibb announced that the United States Food and Drug Administration (FDA) had authorized Breyanzi (lisocabtagene maraleucel), a CAR T-cell treatment, for people with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior regimens. Breyanzi will now be the only CAR T-cell therapy accessible for four unique subtypes of non-Hodgkin lymphoma, expanding therapeutic choices for patients with B-cell malignancies.
In May 2023, AbbVie announced that the FDA has authorized EPKINLY (epcoritamab-bysp), making it the first and only bispecific antibody for treating adult patients with refractory diffuse large B-cell lymphoma. This approval is based on the drug's efficacy in patients who have had two or more prior treatments.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Type, By Drugs |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Seattle Genetics, Inc., Takeda Pharmaceutical Company Ltd., Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories, AstraZeneca, Bayer AG, Novartis AG. |
Key Topics Covered in the Report
- Global Lymphoma Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Lymphoma Treatment Market
- Segmentation of Global Lymphoma Treatment Market By Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma)
- Segmentation of Global Lymphoma Treatment Market By Drugs (Rituxan/MabThera, Revlimid, Imbruvica, Adcetris, Keytruda, Opdivo, Others)
- Statistical Snap of Global Lymphoma Treatment Market
- Expansion Analysis of Global Lymphoma Treatment Market
- Problems and Obstacles in Global Lymphoma Treatment Market
- Competitive Landscape in the Global Lymphoma Treatment Market
- Details on Current Investment in Global Lymphoma Treatment Market
- Competitive Analysis of Global Lymphoma Treatment Market
- Prominent Players in the Global Lymphoma Treatment Market
- SWOT Analysis of Global Lymphoma Treatment Market
- Global Lymphoma Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Lymphoma Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in the Global Lymphoma Treatment Market
7.Global Lymphoma Treatment Market, By Type (USD Million) 2021-2034
7.1.Hodgkin Lymphoma7.2.Non-Hodgkin Lymphoma
8.Global Lymphoma Treatment Market, By Drug (USD Million) 2021-2034
8.1.Rituxan/MabThera8.2.Revlimid8.3.Imbruvica8.4.Adcetris8.5.Keytruda8.6.Opdivo8.7.Others
9.Global Lymphoma Treatment Market (USD Million) 2021-2034
9.1.Global Lymphoma Treatment Market Size and Market Share
10.Global Lymphoma Treatment Market, By Region, (USD Million) 2021-2034
10.1.Asia-Pacific
10.1.1.Australia10.1.2.China10.1.3.India10.1.4.Japan10.1.5.South Korea10.1.6.Rest of Asia-Pacific
10.2.Europe
10.2.1.France10.2.2.Germany10.2.3.Italy10.2.4.Spain10.2.5.United Kingdom10.2.6.Rest of Europe
10.3.Middle East and Africa
10.3.1.Kingdom of Saudi Arabia10.3.2.United Arab Emirates10.3.3.Qatar10.3.4.South Africa10.3.5.Egypt10.3.6.Morocco10.3.7.Nigeria10.3.8.Rest of Middle-East and Africa
10.4.North America
10.4.1.Canada10.4.2.Mexico10.4.3.United States
10.5.Latin America
10.5.1.Argentina10.5.2.Brazil10.5.3.Rest of Latin America
11.Company Profile
11.1.Bristol-Myers Squibb Company
11.1.1.Company details11.1.2.Financial outlook11.1.3.Product summary11.1.4.Recent developments
11.2.Celgene Corporation
11.2.1.Company details11.2.2.Financial outlook11.2.3.Product summary11.2.4.Recent developments
11.3.Merck & Co., Inc.
11.3.1.Company details11.3.2.Financial outlook11.3.3.Product summary11.3.4.Recent developments
11.4.F. Hoffmann-La Roche Ltd.
11.4.1.Company details11.4.2.Financial outlook11.4.3.Product summary11.4.4.Recent developments
11.5.Seattle Genetics, Inc.
11.5.1.Company details11.5.2.Financial outlook11.5.3.Product summary11.5.4.Recent developments
11.6.Takeda Pharmaceutical Company Ltd.
11.6.1.Company details11.6.2.Financial outlook11.6.3.Product summary11.6.4.Recent developments
11.7.Johnson & Johnson
11.7.1.Company details11.7.2.Financial outlook11.7.3.Product summary11.7.4.Recent developments
11.8.Eli Lilly and Company
11.8.1.Company details11.8.2.Financial outlook11.8.3.Product summary11.8.4.Recent developments
11.9.Abbott Laboratories.
11.9.1.Company details11.9.2.Financial outlook11.9.3.Product summary11.9.4.Recent developments
11.10.AstraZeneca
11.10.1.Company details11.10.2.Financial outlook11.10.3.Product summary11.10.4.Recent developments
11.11.Bayer AG
11.11.1.Company details11.11.2.Financial outlook11.11.3.Product summary11.11.4.Recent developments
11.12.Novartis AG
11.12.1.Company details11.12.2.Financial outlook11.12.3.Product summary11.12.4.Recent developments
11.13.Others
12.Conclusion
13.List of Abbreviations
14.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Lymphoma Treatment Market covered By Type, By Drugs
Lymphoma Treatment Market is projected to reach USD 16.88 billion by 2034, growing at a CAGR of 8.58% during the forecast period.
Lymphoma Treatment Market size from 2025. The Market is expected to reach USD 16.88 billion by 2034, at a CAGR of 8.58% during the forecast period.
Lymphoma Treatment Market CAGR of 8.58% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Lymphoma Treatment Market size is USD 16.88 billion from 2025 to 2034.
The North America is anticipated to have the highest Market share in the Lymphoma Treatment Market.
Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Seattle Genetics, Inc., Takeda Pharmaceutical Company Ltd., Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories, AstraZeneca, Bayer AG, Novartis AG.
The report includes an in-depth analysis of the Global Lymphoma Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
